The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of …

Mapping non-canonical cellular pathways affected by approved medications can accelerate
drug repurposing efforts, which are crucial in situations with a global impact such as the …

The current 2019 novel coronavirus disease (COVID-19), an emerging infectious disease, is
undoubtedly the most challenging pandemic in the 21st century. A total of 92,977,768 …

SARS-CoV-2 infection causes COVID-19, which frequently leads to clinical deterioration
and/or long-lasting morbidity. Academic and governmental experts throughout the USA met …

Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …

Repurposing of currently available drugs is a valuable strategy to tackle the consequences
of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on …

We read with great interest the correspondence letters of Salles et al.[1] and Stip et al.[2],
following our multicenter observational retrospective study that showed a substantial …

In a large, multicenter, retrospective cohort study of 83 584 patients with laboratory-
confirmed COVID-19 who had an emergency department or urgent care visit or were …

Background The efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment
of acute COVID-19 is still under investigation, with conflicting results reported from …

To circumvent time-consuming clinical trials, testing whether existing drugs are effective
inhibitors of SARS-CoV-2, has led to the discovery of Remdesivir. We decided to follow this …